Beqalzi Pharmacy Partnership Has Been Announced
Adults with mantle cell lymphoma now have access to a new pharmacy channel for this B-cell lymphoma 2 protein inhibitor.
Updated on Oct. 6, 2026 in Cancer
Live Poll
Do you trust specialty pharmacies to provide better service for complex medication needs than retail pharmacies?
Onco360 has been named a national specialty pharmacy partner for Beqalzi, a treatment for adults with relapsed or refractory mantle cell lymphoma. The drug is indicated for patients who have already received at least two prior lines of systemic therapy, including a BTK inhibitor.
Why it matters
Cancer cells often survive chemotherapy by overexpressing the BCL-2 protein, which Beqalzi works to inhibit. This pharmacy partnership streamlines access for patients requiring this specific class of targeted therapy.
In the BGB-11417-201 study of 103 patients with relapsed or refractory mantle cell lymphoma, Beqalzi achieved an overall response rate of 52.4 percent. The median duration of response observed in this cohort was 15.8 months, with a median time to response of 1.9 months.
The players
Onco360
A Louisville-based national specialty pharmacy focused on providing comprehensive support services for patients undergoing oncology treatments.
BeOne Medicines
A pharmaceutical developer based in Pennington, New Jersey, focused on creating targeted therapies for complex oncological conditions.
The details
Beqalzi acts by binding to the BCL-2 protein, displacing pro-apoptotic proteins to trigger cancer cell death. Treatment requires a cautious four-week ramp-up phase to reach the final 320 mg daily oral dose. This regimen is designed to overcome the resistance mechanisms that mantle cell lymphoma cells develop against traditional chemotherapy agents.
Timeline
October 06, 2026: Onco360 was named a national specialty pharmacy partner.
Health Landscape
The introduction of Beqalzi aligns with the broader medical trend of targeting BCL-2 protein overexpression to treat resistant cancers. It adds another layer to the standard of care for patients who have exhausted multiple lines of systemic therapy.
Patients prescribed Beqalzi should work closely with their oncology team to manage the four-week initial ramp-up phase. If you have been treated for mantle cell lymphoma with prior BTK inhibitors, discuss with your doctor whether this targeted therapy is appropriate for your care plan.
The takeaway
Beqalzi offers a new targeted pathway for patients with treatment-resistant mantle cell lymphoma by inhibiting survival-promoting BCL-2 proteins. Always review your complete medication history and any prior systemic therapies with your physician when evaluating new treatment additions.
Further reading
Learn more about the latest developments in Cancer treatment options and patient care.
More information
For more information on pharmacy services, visit the Onco360 specialty pharmacy official website.
Live Poll
Do you trust specialty pharmacies to provide better service for complex medication needs than retail pharmacies?
